Human iPSC 3D Spheroids for Drug Toxicity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models in biomedical research are costly and inefficient, with limited ability to accurately predict human drug responses due to species differences, leading to high failure rates and safety concerns in human clinical trials.
Innovation Solution
The use of human-induced pluripotent stem cell (iPSC) generated tissue models that mimic human organs and diseases, allowing for 3D structure formation and high-throughput testing of therapeutic compounds, potentially replacing animal models in preclinical and clinical testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal models are used for drug testing, then drug safety and efficacy can be evaluated in a living system, but species differences cause inaccurate prediction of human responses and high failure rates
Solution Approach 1:
The patent creates 3D organoid models that are physical copies of human organs, allowing direct observation of human tissue responses to drugs without species translation. These organoids replicate human organ structure and function, providing accurate predictive data for human drug responses while eliminating the need for animal models.
Solution Approach 2:
The patent introduces human organoids as an intermediary between drug testing and human clinical trials. These organoid models serve as a bridge that provides human-relevant data before human trials, reducing the failure rate by filtering out compounds that would be ineffective or harmful in humans.
2Reliability
If traditional animal models are used, then drug safety can be assessed, but the process is costly and time-consuming with high failure rates in clinical trials
Solution Approach 1:
The patent creates 3D organoid models that are physical copies of human organs, allowing direct observation of human tissue responses to drugs without species translation. These organoids replicate human organ structure and function, providing accurate predictive data for human drug responses while eliminating the need for animal models.
Solution Approach 2:
The patent changes the fundamental parameter of the testing model from animal tissue to human tissue at the organ level. By using human organoids that maintain three-dimensional structure and functional complexity, the system achieves human-relevant drug safety assessment without the time and cost delays inherent in animal model development and translation.
3Productivity
If animal models are used for preclinical testing, then drug efficacy can be demonstrated, but results often fail to replicate in human clinical trials
Solution Approach 1:
The patent creates 3D organoid models that are physical copies of human organs, allowing direct observation of human tissue responses to drugs without species translation. These organoids replicate human organ structure and function, providing accurate predictive data for human drug responses while eliminating the need for animal models.
Solution Approach 2:
Instead of using animal models and hoping results translate to humans, the patent inverts the approach by directly using human organoids for preclinical testing. This inversion ensures that drug efficacy is demonstrated in the actual target species (humans) from the outset, eliminating the translation gap and ensuring consistency between preclinical and clinical results.
Data Source
AI summary
The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.